GUTS - NASDAQ
Fractyl Health, Inc. Common Stock
$0.73
-6.5%Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
At a Glance
Live Snapshotguts
Operating Expenses
Last Annual Value
95.69M
3-Year CAGR
25%
5-Year CAGR
28%
10-Year CAGR
13%
Fractyl Health, Inc. Common Stock Competitors Analysis of Operating Expenses
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Fractyl Health, Inc. Common Stock NASDAQ:GUTS | 95.69M | 23.4% | 21.0% | N/A | |
 Biomea Fusion, Inc. NASDAQ:BMEA | 79.90M | -14.1% | 13.9% | N/A | |
 Quince Therapeutics, Inc. NASDAQ:QNCX | 57.28M | 18.3% | -8.7% | N/A | |
 Adicet Bio, Inc. NASDAQ:ACET | 115.73M | -8.7% | 10.2% | 220.9% | |
 Spruce Biosciences, Inc. NASDAQ:SPRB | 36.51M | -16.2% | -2.8% | N/A | |
 Kalaris Therapeutics Inc NASDAQ:KLRS | 46.14M | 50.8% | -22.8% | N/A | |
 Pliant Therapeutics, Inc. NASDAQ:PLRX | 148.38M | -7.2% | 7.1% | N/A | |
 Surrozen, Inc. NASDAQ:SRZN | 45.03M | 34.4% | -2.5% | N/A | |
 Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL | 145.01M | -21.5% | -7.7% | N/A | |
 aTyr Pharma, Inc. NASDAQ:ATYR | 76.26M | 11.3% | 18.4% | 2.7% | |
 Metagenomi, Inc. Common Stock NASDAQ:MGX | 115.91M | 59.0% | 37.2% | N/A |
Fractyl Health, Inc. Common Stock Fair Value Envelope
Related Guides
Continue your GUTS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.